Beyond the Sting: Can a Genetic Clue Finally Cure Dry Eye Disease?

ZUG, SWITZERLAND – June 09, 2026 – For the millions of people who live with the chronic sting, burn, and blur of Dry Eye Disease (DED), the treatment landscape has long been a frustrating cycle of trial and error. Now, a Swiss biopharmaceutical company is betting that the answer to lasting relief isn't in a one-size-fits-all eyedrop, but in our very own DNA.

Oculis Holding AG has just enrolled the first patient in a pivotal clinical trial, PREDICT-1, for its investigational drug, Licaminlimab. The announcement marks more than just a corporate milestone; it signals the launch of the first-ever registrational trial for DED based on a patient's genetic makeup. By targeting a specific gene variant, Oculis is pioneering a precision medicine approach that could fundamentally reshape how we treat one of the most common and stubbornly persistent eye conditions.

A Vicious Cycle of Frustration

To understand the significance of Oculis's trial, one must first grasp the profound unmet need in Dry Eye Disease. Far from a minor nuisance, DED is a complex, multifactorial disease that disrupts the eye's delicate tear film, leading to inflammation, surface damage, and a cascade of debilitating symptoms. An estimated 10 million people in the U.S. alone suffer from the moderate to severe form of the disease.

Despite a growing arsenal of treatments—from over-the-counter artificial tears to prescription anti-inflammatories like cyclosporine and lifitegrast—patient satisfaction remains alarmingly low. The data paints a grim picture: a staggering 87% of patients feel their chronic condition is not well-managed, and only about 13% report experiencing sustained relief. This lack of efficacy leads to a revolving door of therapies, with an 85-90% discontinuation rate within the first six months of starting a new prescription.

"The current paradigm is often one of frustration for both patients and clinicians," noted one ophthalmologist not involved with the study. "We are caught in a 'trial-and-error' loop because DED is not one disease, but a spectrum of conditions with different underlying causes. A treatment that works for one person might do nothing for another." This heterogeneity is the central challenge that Licaminlimab aims to solve.

The Genetic Key: Targeting TNFR1

The scientific foundation of the PREDICT-1 trial rests on a key player in the body's inflammatory response: Tumor Necrosis Factor-alpha (TNFα). This protein is a well-known driver of inflammation and is implicated in the vicious cycle that perpetuates DED. Licaminlimab is a novel anti-TNFα eye drop, but its true innovation lies in its target.

Previous Phase 2 studies revealed a fascinating insight: the drug's effect was dramatically more pronounced in patients carrying a specific genetic variation in the TNFR1 gene. This gene codes for the primary receptor that mediates TNFα's inflammatory signals. The finding suggests that for a subset of DED sufferers, their genetic makeup predisposes them to a type of inflammation that Licaminlimab is uniquely suited to block.

The PREDICT-1 trial is designed to validate this hypothesis. It will enroll approximately 160 patients, about two-thirds of whom are expected to have the specific TNFR1 genotype. By pre-screening participants, Oculis is focusing its efforts on the population most likely to benefit. The primary goal is to measure the change in ocular discomfort by Day 29 in this genetically-defined group, comparing the drug to a vehicle-only control.

"The advancement of Licaminlimab represents a meaningful progress in dry eye disease research," said Dr. Anat Galor, M.S.P.H., Professor of Ophthalmology at Bascom Palmer Eye Institute, in a statement. "If confirmed in the PREDICT-1 study, this genotype-informed, precision medicine approach has the potential to enable a more targeted treatment strategy for this highly heterogeneous patient population."

A High-Stakes Bet on Precision

For Oculis, the PREDICT-1 trial is a strategic and potentially transformative gamble. Pursuing a genotype-specific therapy is a bold move. On one hand, it narrows the potential market from the entire DED population to a smaller, genetically-defined segment. It also introduces regulatory complexities, as approval may be tied to a companion diagnostic test used to identify eligible patients.

On the other hand, the potential reward is immense. In a crowded market, a drug that offers demonstrably superior efficacy for a specific group of patients—identified with a simple test—could become the undisputed standard of care for that population. It would replace the costly and frustrating 'trial-and-error' process with a targeted, effective solution.

The stakes are particularly high for Oculis, which recently faced a setback when its candidate for diabetic macular edema failed in late-stage trials. The company has since strategically re-focused its resources, making the success of its neuro-ophthalmology and DED programs, including Licaminlimab, all the more critical.

"The first patient randomized in PREDICT‑1 marks an important milestone for Licaminlimab and for the advancement of a genotype‑based, precision medicine approach in dry eye disease, a highly unsatisfied market," commented Riad Sherif, M.D., Chief Executive Officer of Oculis. "By pioneering an innovative development strategy, our objective is to deliver a precision medicine approach that addresses a major unmet need for the millions of underserved patients currently constrained by a trial-and-error method."

As the PREDICT-1 trial gets underway, millions of patients and the entire ophthalmology community will be watching closely. If successful, Licaminlimab could not only provide a powerful new weapon against a pervasive disease but also validate a new paradigm for drug development, proving that in the quest to heal, the most personal clues are sometimes written in our genes.